Showing results (731-740 of 3,868) with videos related to
Sort By:
Pageof 387
Cancer Biology & Therapy|November 30, 2020
Targeted drug delivery using an aptamer against shared tumor-specific peptide antigen of MAGE-A3Chin-Yu Wang, Bai-Ling Lin, Chung-Hsuan ChenCancer Biology & Therapy|February 21, 2018
Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures reviewYangyang LiuCancer Biology & Therapy|April 27, 2016
Production of truncated MBD4 protein by frameshift mutation in DNA mismatch repair-deficient cells enhances 5-fluorouracil sensitivity that is independent of hMLH1 statusSatoshi Suzuki, Moriya Iwaizumi, Stephanie Tseng-Rogenski, et al.Cancer Biology & Therapy|May 6, 2016
YAP controls transcriptional elongation through CKD9 recruitment for proximal pause release: "Hippo-thetical", new therapeutic targets?Fiorina Kyritsi, Douglas K Price, William D FiggCancer Biology & Therapy|November 5, 2020
Nivolumab induced hyperprogressive disease in advanced esophageal squamous cell carcinomaDantong Sun, Dong Liu, Qiaoling Liu, et al.Cancer Biology & Therapy|November 5, 2020
Fruquintinib effectively controlled the advanced small bowel adenocarcinoma progressed after multiple lines of palliative treatment: a case report and literature reviewYuwei Ding, Juan Wang, Ning Zhu, et al.Cancer Biology & Therapy|November 2, 2020
LRRC75A-AS1 targets miR-199b-5p/PDCD4 axis to repress multiple myelomaQuantang Pang, Yanyan Wang, Dapeng Bi, et al.Cancer Biology & Therapy|March 28, 2022
The NF-κB/miR-488/ERBB2 axis modulates pancreatic cancer cell malignancy and tumor growth through cell cycle signalingDuo Han, Shaihong Zhu, Xia Li, et al.Cancer Biology & Therapy|January 29, 2016
Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer modelsJessica D Sun, Qian Liu, Dharmendra Ahluwalia, et al.Cancer Biology & Therapy|February 2, 2016
Resisting resistance: Establishing new treatment options for CRPC patientsShaunna Beedie, William D FiggPageof 387